Were entering a new chapter in weight and metabolic health. While GLP 1s have been in the spotlight, researchers are finding that amylin agonists may offer similar levels of weight loss and were Chronic combination therapy of amylin and GLP 1R analogs results in Download Scientific Diagram Novo's CagriSema loses phase 3 obesity battle against Zepbound Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination